Form 4: TriSalus Life Sciences Director Kerry Hicks Granted 15,000 Stock Options

TriSalus Life Sciences, Inc. Director Kerry R. Hicks was granted 15,000 stock options with an exercise price of $5.50, vesting over one year or at the next annual stockholder meeting.

Summary

• Kerry R. Hicks, a Director of TriSalus Life Sciences, Inc. (TLSI), was granted 15,000 Director Stock Options on June 12, 2025.
• The options have an exercise price of $5.50 per share.
• These options are scheduled to fully vest on the one-year anniversary of the grant date (June 12, 2026) or on the date of the Issuer's next annual stockholder meeting, whichever is earlier, contingent on Mr. Hicks' continued service with the Issuer.
• The expiration date for these stock options is June 11, 2035.
• Following this transaction, Mr. Hicks beneficially owns a total of 89,222 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a routine compensation event that aligns management incentives with shareholder interests, indicating standard corporate governance practices and a positive alignment of interests.

Positives

• The grant of 15,000 stock options to Director Kerry R. Hicks aligns his financial interests with the long-term performance and shareholder value creation of TriSalus Life Sciences, Inc.
• The options have a long expiration date of June 11, 2035, providing a significant window for potential value realization based on future stock price appreciation.

Risks

• The vesting of the 15,000 stock options is contingent on the Reporting Person's continued service with TriSalus Life Sciences, Inc.

Future Outlook

The 15,000 stock options granted to Director Kerry R. Hicks are scheduled to fully vest on the one-year anniversary of the grant date (June 12, 2026) or at the Issuer's next annual stockholder meeting, whichever occurs first, contingent on his continued service.

Industry Context

This Form 4 filing details a standard equity compensation grant to a director, a common practice across industries to incentivize long-term performance and align management interests with shareholder returns.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholder value creation, but also represents potential future dilution if the options are exercised.
• Director (Kerry R. Hicks): Receives potential future compensation tied to the company's stock performance, incentivizing continued service and strategic contributions.

Next Steps

• The stock options will vest on the one-year anniversary of the grant date (June 12, 2026) or at the next annual stockholder meeting, subject to continued service.
• Kerry R. Hicks may exercise the vested options to acquire common stock at the exercise price of $5.50 per share before the expiration date of June 11, 2035.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, stock options, insider transaction, Form 4, director compensation, equity grant, beneficial ownership